FDA Brief

Warning letters Drugs

FDA warning letter to

CofixRx, LLC

High riskIssued Apr 5, 2022Posted Apr 8, 2022Center for Drug Evaluation and Research | CDER

FDA warned CofixRx that its CofixRX Nasal Spray is an unapproved, misbranded drug sold with COVID-19 prevention claims.

What happened

On January 4, 2022, FDA reviewed the website cofixrx.com and the labeling on CofixRX Nasal Spray packaging. FDA found the non-alcohol-based antiseptic sold as intended to mitigate, prevent, treat, diagnose, or cure COVID-19 and other conditions, with label and website claims such as destroying SARS-CoV-2 and cold and flu viruses in 15 seconds and lasting up to 8 hours. FDA said the product is an unapproved new drug and a misbranded drug.

What FDA found

  1. CofixRX Nasal Spray is a new drug (a drug not generally recognized as safe and effective) sold without FDA approval.

    section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  2. The product's label and website claims that it destroys SARS-CoV-2 and prevents cold and flu viruses make it a drug intended to prevent or treat disease.

    section 201(g)(1)(B) and (C) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), (C)
  3. The product is misbranded because its labeling misleadingly suggests CofixRX is FDA approved.

    section 502(a) of the FD&C Act, 21 U.S.C. 352(a)
  4. The product is misbranded because it is a nonprescription drug that does not meet the requirements for marketing without an approved application.

    section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee); section 505G, 21 U.S.C. 355h
  5. The product does not conform to the applicable over-the-counter antiseptic tentative final monograph or other rule, including because it is intended for use inside the nostrils and makes time-specific efficacy claims.

    section 505G(a)(3) of the FD&C Act, 21 U.S.C. 355h(a)(3); 1994 TFM, 59 FR 31402, as amended
  6. Its introduction into interstate commerce is prohibited because it is an unapproved and misbranded drug.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. 331(a), (d)

What FDA wants

FDA tells CofixRx to take immediate action to stop selling unapproved and unauthorized COVID-19 products and to review its websites, labels, and promotional materials for misleading claims. Within 48 hours, the company must email the COVID-19 Task Force describing the steps taken to address the violations and prevent recurrence, or explain why it cannot do so and when it will.

Who should pay attention

  • companies selling nasal antiseptic or COVID-19-related health products
  • retailers and distributors of over-the-counter antiseptic products
  • firms making antiviral or virus-prevention claims for non-drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk